Crossmark

HRAS‐driven cancer cells are vulnerable to TRPML1 inhibition

Crossref DOI link: https://doi.org/10.15252/embr.201846685

Published Online: 2019-02-20

Published Print: 2019-04

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Jung, Jewon

Cho, Kwang‐Jin

Naji, Ali K

Clemons, Kristen N

Wong, Ching On

Villanueva, Mariana

Gregory, Steven

Karagas, Nicholas E

Tan, Lingxiao

Liang, Hong

Rousseau, Morgan A

Tomasevich, Kelly M

Sikora, Andrew G

Levental, Ilya

van der Hoeven, Dharini

Zhou, Yong

Hancock, John F

Venkatachalam, Kartik https://orcid.org/0000-0002-3055-9265
Funding

Funding for this research was provided by:

National Institutes of Health (R01NS08130)

National Institutes of Health (R21NS094860)

National Institutes of Health (R00CA188593)

Cancer Prevention and Research Institute of Texas (#170691)

Cancer Prevention and Research Institute of Texas (RP170233)

National Cancer Institute (P30CA125123)

National Cancer Institute (R00CA188593)
License Information

Version of Record valid from 2019-02-20
More Information

Publication History

Received: 2018-07-03

Accepted: 2019-02-01

Published: 2019-02-20